Datopotamab Deruxtecan：EGFR-TKI + 铂化疗后的 TROP2 ADC 监管进展
类型: FDA 批准 / ADC 发表日期: 2025-06-23 入库日期: 2026-05-21 来源: FDA / TROPION-Lung05 标签: EGFR L858R, Datopotamab deruxtecan, TROP2 ADC, 奥希替尼后, 铂化疗后, FDA
Citation
FDA. FDA approves datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung cancer. 2025. FDA approval notice
Related PubMed search term: TROPION-Lung05 datopotamab deruxtecan EGFR-mutated NSCLC.
Why it matters for mom
Mom's course overlaps the population regulators are now focusing on: EGFR-mutated NSCLC after EGFR-directed therapy and platinum chemotherapy. Dato-DXd is a TROP2-directed ADC, and it should be on the later-line/trial watchlist.
Practical takeaways
- Dato-DXd is relevant after EGFR TKI and platinum exposure.
- It is a later-line systemic option, not a reason to stop current effective therapy.
- Toxicity profile and access in China/US need checking at the actual decision point.
Questions for doctors
- Is Dato-DXd available or trial-accessible where mom is treated?
- How would doctors compare Dato-DXd vs HER3-DXd vs amivantamab-chemotherapy if progression is confirmed?
- Given prior chemotherapy-related cytopenias, what toxicity would be most limiting?